The bill aims to combat the illicit use of xylazine. It defines "xylazine" and adds it to schedule III of the Controlled Substances Act. The bill also amends certain provisions related to xylazine, such as labeling, practitioner registration, and manufacturer transition. Furthermore, it requires the United States Sentencing Commission to review and potentially amend sentencing guidelines for offenses involving xylazine. The bill mandates the Attorney General to submit reports to Congress on the prevalence and impact of illicit xylazine use. It aims to address the illicit use and trafficking of xylazine in the United States.